Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single- and multiple-dose study of KK4408 in healthy male volunteers
jRCT2071260064Phase 1Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, double-blind trial of KK4408 (5 cohorts), sponsored by Kyowa Kirin. Primary endpoints: Treatment-emergent adverse events, Laboratory values and 4 more. Started Oct 2026; status: recruiting.
02
Drugs
KK4408
Beyond the preview
Go deeper on jRCT2071260064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260064.